Introduction
============

Brugada syndrome (BrS) -- a heritable arrhythmic disease responsible for sudden cardiac death (SCD) in patients with structurally normal hearts -- was first reported by [@B7]. It accounts for 4% of all sudden deaths and up to 20% of sudden deaths in patients without structural cardiac disease ([@B4]), and has been identified as the same entity previously designated as sudden unexpected nocturnal death syndrome (SUNDS) ([@B41]). Moreover, the prevalence of BrS is highest in the Asian population ([@B21]), which may be attributed to a distinct genetic background.

Numerous genes are associated with BrS, including *SCN5A*, *SCN10A*, *SCN1B*, *SCN2B*, *SCN3B*, *KCNH2*, *KCND2*, *KCND3*, *KCNE3*, *KCNE5*, *KCNJ8*, *CACNA1C*, *CACNA2D1*, *CACNB2*, *ABCC9*, *HCN4*, *PKP2*, *SLMAP*, *TRPM4*, *RANGRF*, *GPD1L*, *FGF12*, and *SEMA3A* ([@B13]); most encode proteins that control the transmembrane ion currents responsible for electrical impulses. The identification of pathogenic variants is crucial because it can help further investigation of the disease mechanism and facilitate family screening. To determine the pathogenicity of a variant, the American College of Medical Genetics and Genomics (ACMG) suggests taking into consideration the population allele frequency, the effect on protein structure, and the results of functional studies ([@B35]).

The expected allele frequency of a causative variant is related to the disease prevalence, the penetrance, and to the genetic contribution made by the causative variant to the disease ([@B43]). In other words, the prevalence of a monogenic disease is the summation of the contributions of all the pathogenic variants in a population. The expected allele frequency of each variant can vary across populations, depending on its contribution to the monogenic disease. Therefore, the pathogenicity of a variant with an allele frequency much higher than expected should be investigated carefully. The first universal genome-wide study regarding allele frequency was the 1000 Genomes Project (1000G). As the sample size increased in the Exome Aggregation Consortium (ExAC) and then the Genome Aggregation Database (gnomAD), it was expected that these studies would become more representative of the true population frequency. Ancestral differences in numerous variants were revealed, and some previously reported pathogenic variants have been reclassified as benign or disease-predisposing owing to their high frequencies in some ancestries ([@B27]; [@B10]). Although there have been functional *in vitro* studies of some of these variants, they could be considered disease-predisposing in high-frequency ancestries because the polymorphism of genes among ancestries is complex and may have protective effects.

Therefore, a local reference for population frequency is invaluable in determining the pathogenicity of a variant in a given ancestry. Current large-scale ancestry-specific databases for population frequency include the Taiwan Biobank (TWB), the integrative Japanese Genome Variation Database (iJGVD), and the NHLBI Grand Opportunity Exome Sequencing Project (ESP6500) for European Americans (EAs) and African Americans (AAs).

The present study was performed to investigate the ancestral differences in previously reported pathogenic variants of BrS, with the expectation that the pathogenicity of variants with relatively high allele frequencies in some ancestries should be reassessed. Because the prevalence of BrS is highest in the Asian population, we used our BrS cohort (TW-BrS registry) to validate the clinical impact of these variants, which were listed as disease-causing or pathogenic variants in the Human Gene Mutation Database (HGMD) and ClinVar.

Materials and Methods {#s1}
=====================

Acquisition of Reported Pathogenic Variants
-------------------------------------------

We collected the pathogenic and likely pathogenic variants of BrS reported in ClinVar^[1](#fn01){ref-type="fn"}^ ([@B24]), and the disease-causing mutations in HGMD - Professional^[2](#fn02){ref-type="fn"}^ ([@B39]) throughout April 2017.

Identification of Variants With High Allele Frequencies in Any Ancestry
-----------------------------------------------------------------------

We compared the allele frequency of each variant among different ancestries by searching gnomAD version 2.0, TWB, and iJGVD. gnomAD was first released as ExAC in 2013 ([@B26]), and was expanded to 123,136 exomes and 15,496 genomes in 2017. TWB was released in 2014, and is composed of whole-genome sequencing data from 997 unrelated Han Chinese (HC), and genome-wide association study data from 16,036 unrelated HC ([@B12]). No subjects with BrS were enrolled in the TWB. iJGVD was first released in 2014 ([@B31]), and consists of whole-genome sequencing data from 3,554 Japanese subjects (3KJPNv2) obtained in June 2018.

According to the clinical genetic interpretation method proposed by [@B43], in addition to considering the disease prevalence and penetrance, it is also necessary to consider the allelic contribution made by each pathogenic variant. Accordingly, the maximal credible allele frequency of a pathogenic variant is as follows:
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Brugada syndrome has the highest prevalence (∼0.12%) in East Asian populations ([@B30]; [@B21]), with a genetic yield rate of approximately 30--35% ([@B20]), and the contribution of a single variant is no more than 1% ([@B23]). Moreover, BrS-associated variants may have a penetrance of approximately 16--32.7% according to familial co-segregation analysis ([@B32]; [@B15]). Therefore, the allele frequency of a pathogenic variant of BrS is expected to be lower than 0.000075, implying that the pathogenicity of any variants with allele frequencies higher than this value may require careful interpretation. However, *in vitro* studies have revealed that some variants are associated with functional alterations ([@B29]). Such cases should be treated as disease predisposition alleles rather than totally excluding their pathogenic role. Thus, we used a conservative cut-off of 0.001, at least 10 times higher than the frequency mentioned above, which may have prevented the exclusion of some true pathogenic variants from the subsequent phenotype-driven analysis due to too strict a cut-off. The cut-off set by us in the present study was not very strict, and was reasonable as the first step for the reclassification of previously reported pathogenic variants of BrS across different populations.

Study Cohort
------------

The present study complied with governmental laws and regulations and was carried out in accordance with the Good Practice guidelines provided by Research Ethics Committee B of the National Taiwan University Hospital. All subjects provided written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by Research Ethics Committee B of the National Taiwan University Hospital. We enrolled 124 consecutive unrelated BrS patients from the Han Chinese population of Taiwan between 1998 and 2017 (SADS-TW BrS registry) ([@B44]). The majority (89.4%) of the patients were male, and their mean age was 44.7 years old. The diagnosis of BrS was in accordance with the expert consensus of the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the Asia-Pacific Heart Rhythm Society (APHRS) ([@B3]; [@B34]). The Brugada electrocardiographic (ECG) patterns are composed of three types as follows: type 1 ECG has coved-type ST-segment elevation with J point elevation \>0.2 mV, followed by a negative T wave; type 2 ECG has saddle-back ST-segment elevation with J point elevation \>0.2 mV, followed by a gradually descending ST-segment elevation \>0.1 mV and a positive or biphasic T wave; and type 3 ECG has either a saddle-back or coved appearance but with ST-segment elevation \<0.1 mV. Only spontaneous or drug-induced type 1 ECG is diagnostic, while type 2 or 3 ECG is suspicious and should undergo drug provocation test by sodium channel blocker. The demographic data were recorded, including gender, age, initial presentation, family history of sudden cardiac death or BrS and electrocardiographic parameters.

Sanger's Sequencing
-------------------

With permission from patients, 10 ml of peripheral venous blood was used for genetic analysis. We used deoxyribonucleic acid (DNA) extraction kit (Qiagen company) to extract DNA from the buffy coat of patients' peripheral blood. *SCN5A* variants were screened by Sanger's sequencing. We investigated the prevalence and clinical characteristics of the patients with these reclassified variants in our 124 consecutive unrelated BrS cohort.

Statistical Analysis
--------------------

Chi-square or Fisher's exact tests were used to compare categorical variables. A two-tailed *p*-value \< 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics for Windows (version 22.0) (Armonk, NY, United States).

Results
=======

Four-hundred and five disease-causing mutations of BrS were reported in HGMD, and 45 pathogenic and 23 likely pathogenic variants were reported in ClinVar. There were 440 variants in total, with 33 overlapping variants. A total of 385 (87.5%) variants were in the SCN5A gene, followed by the CACNA1C, SCN10A, and TRPM4 genes (Figure [1](#F1){ref-type="fig"}). Twenty-three (6.0%) SCN5A variants were in the voltage-sensing domain (VSD), 52 (13.5%) were in the pore-forming domain, 53 (13.8%) were in other transmembrane domains, 114 (29.6%) were in the extracellular domain, and 143 (37.1%) were in the cytoplasmic domain.

![The distribution of pathogenic and likely pathogenic variants. **(A)** *SCN5A* accounts for 87.5%. **(B)** The remaining genes.](fgene-09-00680-g001){#F1}

Of the 440 previously reported BrS mutations, 18 (4.1%) variants had an allele frequency ≥0.001 in at least one ancestry (Table [1](#T1){ref-type="table"}): 17 from HGMD and 1 from ClinVar. There was no significant difference in the percentages of variants found in these two databases (HGMD 4.2% versus ClinVar 1.5%, *p* = 0.4915). All of the original studies used internal controls with 50--700 healthy subjects; four of them used two controls (2: internal controls and ESP6500; 2: internal controls and 1000G). None of the original studies used greater than 3 controls. Eleven of the 18 variants (61.1%) in the previous 13 studies used the Caucasian population as healthy controls. These variants included 6 SCN5A and 12 non-SCN5A variants. There were more previously reported non-SCN5A variants with allele frequencies ≥0.001 than SCN5A variants (21.8 versus 1.6%, *p* \< 0.0001). Among the SCN5A variants with allele frequencies ≥0.001, one was located in the VSD, one in the pore-forming domain, one in another transmembrane domain, and the other three variants were in the cytoplasmic domain (Figure [2](#F2){ref-type="fig"}). The variants with allele frequencies \<0.001 across all ancestries are listed in Supplementary Table [1](#SM1){ref-type="supplementary-material"}.

###### 

The 18 of the 440 reported pathogenic variants in Brugada syndrome showed allele frequencies ≥0.001 in at least one ancestry.

  Gene                        Transcript    ΔNA          ΔAA      dbSNP         Controls of the original study                                                                HGMD                         gnomAD (total *n* = 138.632)   3KJPNv2 (*n* = 3,554)   TWB (*n* = 997)      SIFT                 Polyphen-2                                                                                         
  --------------------------- ------------- ------------ -------- ------------- --------------------------------------------------------------------------------------------- ---------------------------- ------------------------------ ----------------------- -------------------- -------------------- ------------------- ------------------- -------------------- ----------- ------------- ----------- -------------------
  **Variants from HGMD**                                                                                                                                                                                                                                                                                                                                                                                       
  ABCC9                       NM_005691.3   3589C \> T   R1197C   rs778849288   \>200 Caucasians                                                                              DM ([@B17])                  0.000024                       0                       0                    0                    0                   0.001431^∗^         0.000032             0           0.002008^∗^   Damaging    Probably damaging
  CACNA1C                     NM_000719.6   6388G \> A   D2130N   rs199473392   \>200 Caucasians                                                                              DM ([@B8])                   0.000046                       0                       0                    0                    0.002504^∗^         0                   0                    0           0             Damaging    Possibly damaging
  HCN4                        NM_005477.2   2522C \> T   S841L    rs200546024   \>700 Caucasians, 1000G                                                                       DM ([@B11])                  0.000058                       0                       0.000058             0.000085             0.001802^∗^         0                   0                    0           0             Damaging    Probably damaging
  KCNB2                       NM_004770.2   1564G \> A   E522K    rs745516217   500 Han Chinese                                                                               DM ([@B22])                  0.000024                       0                       0                    0                    0                   0.001538^∗^         0                    0.0013^∗^   0.001003^∗^   Tolerated   Probably damaging
  KCNT1                       NM_020822.2   3317G \> A   R1106Q   rs561255614   500 Han Chinese                                                                               DM ([@B22])                  0.000062                       0                       0                    0.000053             0                   0.004356^∗^         0.000327             0.0027^∗^   0.004692^∗^   Damaging    Probably damaging
  PKP2                        NM_004572.3   1093A \> G   M365V    rs143900944   200 Caucasians, ESP                                                                           DM ([@B9])                   0.000237                       0                       0                    0                    0                   0                   0.001137^∗^          0           0             Tolerated   Benign
  RANGRF                      NM_016492.4   181G \> T    E61^∗^   rs140704891   300 Spanish                                                                                   DM ([@B38])                  0.005406^∗^                    0.01116^∗^              0.001018^∗^          0.000587             0.000297            0                   0.001657^∗^          0           0             NA          NA
  SCN3B                       NM_018400.3   328G \> A    V110I    rs147205617   480 Japanese                                                                                  DM ([@B19])                  0.000032                       0                       0.000029             0.000583             0                   0.002438^∗^         0.000455             0.0025^∗^   0.003009^∗^   Tolerated   Probably damaging
  SCN5A                       NM_198056.2   80G \> A     R27H     rs199473045   400 Caucasians                                                                                DM ([@B33])                  0.000024                       0                       0.001569^∗^          0.000208             0                   0.000159            0                    0           0             Damaging    Probably damaging
  SCN5A                       NM_198056.2   677C \> T    A226V    rs199473561   400 Caucasians                                                                                DM ([@B33])                  0.000008                       0                       0                    0                    0                   0.001357^∗^         0                    0           0.001508^∗^   Damaging    Probably damaging
  SCN5A                       NM_198056.2   3068G \> A   R1023H   rs199473592   200 Japanese; ESP                                                                             DM ([@B42])                  0.000048                       0                       0.000174             0.000042             0                   0.000053            0.001887^∗^          0           0             Tolerated   Benign
  SCN5A                       NM_198056.2   3727G \> A   D1243N   rs199473599   649 white, 651 non-white subjects, 200--400 Caucasians                                        DM ([@B23])                  0.000024                       0.000078                0.000116             0                    0.002758^∗^         0.000053            0.000065             0.0001      0             Damaging    Probably damaging
  SCN5A                       NM_198056.2   4018G \> A   V1340I   rs199473605   649 white, 651 non-white subjects (blacks, Asians, Hispanics, and others), 200--400 Indians   DM ([@B23])                  0.000024                       0                       0                    0.000042             0                   0.000371            0.000065             0           0.001003^∗^   Damaging    Probably damaging
  SCN10A                      NM_006514.3   41G \> T     R14L     rs141207048   \>200 Caucasians                                                                              DM ([@B16])                  0.002776^∗^                    0.000931                0.000872             0.000375             0.009374^∗^         0                   0.000162             0           0             Damaging    Possibly damaging
  SCN10A                      NM_006514.3   3803G \> A   R1268Q   rs138832868   \>200 Caucasians                                                                              DM ([@B16])                  0.003162^∗^                    0.002957^∗^             0.000436             0.000542             0.000592            0.000319            0.000033             0.0001      0.000502      Damaging    Probably damaging
  SCNN1A                      NM_001038.5   1049G \> A   R350Q    rs534158738   500 Han Chinese                                                                               DM ([@B22])                  0.000036                       0.000066                0                    0                    0.000465            0.000033            0                    0.001       0.001505^∗^   Damaging    Probably damaging
  SLMAP                       NM_007159.3   2129A \> C   E710A    rs765326482   94--380 Japanese, 1000G                                                                       DM ([@B18])                  0                              0                       0                    0                    0                   0.000988            0                    0.0014^∗^   0             Tolerated   Possibly damaging
  **Variants from ClinVar**                                                                                                                                                                                                                                                                                                                                                                                    
  Gene                        Transcript    ΔNA          ΔAA      dbSNP         Ethnicity of the original study                                                               ClinVar (reported date)      gnomAD (total *n* = 138.632)   3KJPNv2 (*n* = 3,554)   TWB (*n* = 997)      SIFT                 Polyphen-2                                                                                         
                                                                                                                                                                                                           NFE (*n* = 63,369)             FIN (*n* = 12,897)      AMR (*n* = 17,210)   AFR (*n* = 12,020)   JEW (*n* = 5,076)   EAS (*n* = 9,435)   SAS (*n* = 15,391)                                         
  SCN5A                       NM_198056.2   5770G \> A   A1924T   rs137854603   50 Caucasians                                                                                 P/LP (2016/07/07) ([@B36])   0.000016                       0                       0.000087             0                    0.001084^∗^         0                   0                    0           0             Tolerated   Possibly damaging
                                                                                                                                                                                                                                                                                                                                                                                                               

1000G, 1000 genomes project; AFR, African; AMR, Latino; ΔAA, amino acid change; ΔNA, nucleotide change; DM, disease-causing mutation; EAS, East Asian; ESP, NHLBI Grand Opportunity Exome Sequencing Project; NFE, non-Finnish European; FIN, Finnish; HGMD, The Human Gene Mutation Database; JEW, Ashkenazi Jewish; 3KJPNv2, Japan Biobank; LP, likely pathogenic; NA, not available; P, pathogenic; SAS, South Asian; TWB, Taiwan Biobank;

∗

≥0.001.

![The distribution of the previously reported *SCN5A* variants with allele frequency ≥0.001 in at least one ancestry. Brown: pore-forming domain; +: voltage-sensing domain. Data from gnomAD, iJGVD, and Taiwan Biobank.](fgene-09-00680-g002){#F2}

With regard to ancestral differences, 14 (77.8%) variants had allele frequencies ≥0.001 only in Asian population, including all the non-SCN5A variants except one RANGRF variant and two SCN10A variants. The allele frequencies of RANGRF p.E61^∗^ were ≥0.001 across all ancestries except for African, whereas the allele frequencies of SCN5A p.R27H were ≥0.001 only in American ancestries. These findings demonstrate that ancestral differences impact genetic predisposition in BrS.

Five variants had allele frequencies ≥0.001 in 1000G or ESP, but they were lower in gnomAD (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Because a larger database is more representative of the population frequency, the results from gnomAD should be more reliable than those reported previously.

Regarding the types of mutations, there were 40 nonsense (9.1%), 73 frameshift (16.6%), 23 splice site (9.1%), and 304 missense (69.1%) mutations among the previously reported 440 BrS mutations. The percentages of the 18 variants with minor allele frequency \>0.001 in at least one ancestry within each type of mutation were: 0% (0/73) in the frameshift mutations, 2.5% (1/40) in the nonsense mutations, 0% (0/23) in the splice site mutations, and 5.6% (17/304) in the missense mutations. There was a significantly lower percentage of radical mutations (frameshift plus nonsense) than missense mutations (0.9 versus 5.6%, *p* = 0.032).

In our SADS-TW BrS registry cohort, for the variants with minor allele frequencies ≥0.001, two SCN5A variants (p.A226V and p.V1340I) (0.45%) were identified in 5 patients (4%) (Table [1](#T1){ref-type="table"}). Of those patients, 4 carried p.A226V and one had p.V1340I. The clinical characteristics of the patients are shown in Table [2](#T2){ref-type="table"}. Among the three patients carrying SCN5A p.A226V underwent the electrophysiological examinations, ventricular tachycardia/fibrillation was induced in two patients. In the other hand, we also found 10 pathogenic or likely pathogenic *SCN5A* variants with minor allele frequencies \<0.001 in 10 patients with BrS (8.1%), for which the pathogenicity was determined according to the American College of Medical Genetics and Genomics (ACMG) criteria ([@B35]).

###### 

Clinical characteristics of the patients (SADS-TW BrS registry) carrying previously reported pathogenic variants in HGMD with allele frequencies ≥0.001 in at least one ancestry.

  No.   Presentation   Gender   Age at first^3^   Occurrence of type 1 BrP   Family history of SCD   Electrophysiology study   Amino acid change   dbSNP         HGMD   gnomAD_EAS   TWB        Reference
  ----- -------------- -------- ----------------- -------------------------- ----------------------- ------------------------- ------------------- ------------- ------ ------------ ---------- ----------------
  1     Syncope        Male     23                Drug-induced               No                      Inducible Vf              A226V               rs199473561   DM     0.001357     0.001508   [@B33]; [@B40]
  2     Asymptomatic   Male     54                Drug-induced               Yes                     Inducible Vf                                                                               
  3     Chest pain     Male     74                Spontaneous                No                      N/A                                                                                        
  4     Syncope        Male     30                Drug-induced               No                      No inducible Vf                                                                            
                                                                                                                                                                                                
  5     Syncope        Male     51                Spontaneous                No                      N/A                       V1340I              rs199473605   DM     0.000371     0.001003   [@B37]; [@B23]
                                                                                                                                                                                                

BrP, Brugada-type electrocardiographic pattern; BrS, Brugada syndrome; DM, disease-causing mutation; EAS, East Asian; N/A, not available; SCD, sudden cardiac death; TWB, Taiwan Biobank; Vf, ventricular fibrillation. Transcript: NM_198056.2.

Discussion
==========

In dealing with a heritable disease, the identification of the causative genetic variant is important for familial consultation, because it can aid risk stratification in a family and eliminate the anxiety of unaffected members. In the era of precision medicine, misinterpretation of variants may lead to incorrect genetic diagnoses and ineffective treatment strategies.

Brugada syndrome is characterized by the loss of the epicardial action potential dome in the right ventricular outflow tract ([@B2]); thus, variants that alter channel function are potential pathogenic variants. Given that BrS is a rare disease, the allele frequency of each pathogenic variant would be expected to be lower than its prevalence. That is, a variant with a functional alteration but a relatively high allele frequency may not be pathogenic by itself, or may only increase susceptibility to the disease.

With the development of next-generation sequencing (NGS), population frequency studies can be conducted faster and on a larger scale, and the pathogenicity of variants can be evaluated on the basis of ancestry-specific references. For example, the *SCN5A* p.R1193Q substitution, which accelerates the inactivation of sodium channels ([@B41]), is now considered to be a disease predisposition allele rather than a causative mutation in Asian populations; its allele frequency in this ancestry is as high as 0.05 ([@B29]), which is much higher than the disease prevalence rate. Another example involves *SCN5A* c.2893C \> T (p.R965C), which exhibits major differences in allele frequency among ancestries (Figure [3](#F3){ref-type="fig"}). These findings support the importance of establishing a large, population-specific database of allele frequency, which could be the best reference for determining the rarity of variants.

![*SCN5A*, c.2893C \> T, p.R965C as an example of ancestral differences in allele frequency.](fgene-09-00680-g003){#F3}

In the present study, we identified 18 variants with minor allele frequencies ≥0.001 in at least one ancestry, indicating that they may be common variants in these populations. In the poly-ancestry population databases, the number of participants in gnomAD is larger than that in 1000G (poly-ancestry) and ESP6500 (European ancestry and African Americans only) whereas in the population-specific databases, TWB (Han Chinese) and iJGVD (Japanese) are probably larger than most internal controls from an individual institution. As a result, the allele frequency in gnomAD, TWB and iJGVD were more approximate to the true allele frequencies of each ancestry. Importantly, 14 (77.8%) of the variants had allele frequencies ≥0.001 only in Asian population. This may imply the distinct genetic background of Asian BrS patients and a different pathogenicity of the same variants in BrS patients across populations. Some variants with definite effects on transmembrane currents, or those predicted to be deleterious by *in silico* analysis, may be reclassified as disease predisposition alleles; however, the pathogenicity of other variants should be subjected to further careful investigation. Since most of these studies used Caucasian population as healthy controls, the MAF in other ancestries could not be known. Therefore, a large database collected from all ancestries is crucial, and variants with allele frequencies \<0.001 across all ancestries (European, African, American, and Asian) are much more likely to be pathogenic.

Our study revealed that significantly more previously reported non-*SCN5A* variants than *SCN5A* variants should be reclassified. This finding is consistent with the findings of [@B25], who showed that there was a higher percentage of BrS cases with rare functional variants in *SCN5A* than in non-*SCN5A* genes, compared with internal controls. There are several possible explanations. First, there have been many comprehensive *in vitro* electrophysiological functional studies of *SCN5A*. The authors of all such studies investigated each variant repeatedly and rigorously, and were therefore able to exclude any variant for which pathogenicity could not be demonstrated. However, studies regarding other genes have usually been small-scale and of limited scope, and may not have excluded some benign variants. Second, *SCN5A* plays an important role in cardiac development and function; thus, non-synonymous variants that alter protein function may directly enhance disease development. Thus, non-*SCN5A* variants should be interpreted carefully.

The substitution of the amino acids that constitute the pore-forming domain of SCN5A may alter its gating function; therefore, this domain should be more highly conserved in evolution across different ancestries than other regions. Alterations to the pore function may be less well tolerated than changes in other regions, which could explain the consistently low allele frequencies of pore-forming domain variants among the databases examined.

Regarding the types of mutations, only 0.9% of the nonsense and frameshift mutations had allele frequencies ≥0.001 in at least one ancestry (European, African, American, or Asian), a significantly lower percentage than that of the missense mutations (5.6%). This difference may imply that BrS-associated nonsense and frameshift mutations are much more likely to be pathogenic, which may be attributed to critical alterations in protein function in these types of mutations.

We found that 4% of the patients with BrS in our cohort carried *SCN5A* variants with minor allele frequencies ≥0.001. Of these patients, four had p.A226V and one had p.V1340I. *SCN5A* p.A226V is located in the VSD, and p.V1340I is located in the pore-forming domain; both reduce the sodium current in patch-clamp studies ([@B37]; [@B40]). However, in a Singaporean family reported by Tan et al., the father carrying p.A226V did not show type 1 Brugada ECG after flecainide infusion. This suggested that the pathogenicity of p.A226V may be questionable in the East Asian population, demonstrating that considering ancestral difference and clinical data is as important as functional studies when we interpret the pathogenicity of a genetic variant.

There are several possible reasons why a variant that causes functional alterations *in vitro* could be a disease predisposition allele in at least some ancestries. First, because protein--protein interactions are complicated in living cells, the effects of variants in transfected cells may not always persist *in vivo*, where a gene that does not encode an ion channel may nevertheless alter the current by interacting with that channel ([@B9]). Second, a pathogenic variant may be masked by another variant ([@B28]), and an ancestry with an abundance of such protective variants could be resistant to this pathogenic variant. Third, deoxyribonucleic acid (DNA) methylation is known to regulate gene expression and is highly divergent among ancestries ([@B14]). Therefore, functional studies are essential, and ancestral differences should be taken into account when judging the pathogenicity of a novel variant.

Limitations
-----------

The present study has limitations. First, more evidences emerged now that the inheritance underlying BrS may be complex with multiple genes and possibly some environmental factors contributing to the phenotype, and some common variants may also be contributive ([@B6]; [@B1]; [@B5]). Therefore, we may not be able to exclude possible contribution to pathogenicity of a variant in polygenic model solely because of its high allele frequency. Second, because electrocardiograms are generally not available in the public control databases, it is possible that some asymptomatic individuals carrying pathogenic BrS-associated variants might be enrolled as "apparently healthy" controls in the public databases. However, considering Brugada syndrome is a rare disease with the prevalence of 12/10,000 (Southeast Asia populations) and 5/10,000 (Caucasians) in the general populations, and healthy controls are usually enrolled randomly from a general population, the expected contribution from the minor allele of BrS-associated variants to the public control databases could be very low (0--0.06%). Third, although TWB and iJGVD are the population-specific references for Han Chinese and Japanese populations, respectively, the number of the samples in the two references are relatively small compared with gnomAD. Therefore, the representativity for the two populations and the power of excluding benign variants may also be a concern. Fourth, if a potentially pathogenic BrS-related variant is "protected" by other genes or by epigenetic effects, its pathogenic phenotype may be attenuated. As a result, its allele frequency in a population may be relatively high. However, this variant may remain pathogenic in other populations or segments of the population; for example, for one gender or in certain ancestries. In such a case, the variant would have been considered to have "questionable pathogenicity" in our study and would require periodic re-evaluation.

In conclusion, the allele frequencies of BrS variants differ significantly with ancestry. This finding should be taken into consideration before judging a variant as pathogenic, particularly in the case of non-*SCN5A* variants, which may be pathogenic in some ancestries but only disease-predisposing in others. Besides, in-house controls and small-scale databases of population frequency have less power to exclude benign variants; large-scale super-controls, such as gnomAD and ancestry-specific databases, could be used to address this issue.
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